Peter Grell
Masaryk University
31 Papers
56 Citations
Peter Grell is an academic researcher from Masaryk University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 4, co-authored 22 publications.
Chat about Author
Papers
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Kevin J. Harrington,Robert L. Ferris,Maura L. Gillison,Makoto Tahara,Jérôme Fayette,Michael Schenker,Åse Bratland,John Walker,Peter Grell,Caroline Even,C. Chung,Rebecca Redman,Alexandre Coutte,Sébastien Salas,Cliona Grant,Sergio J Azevedo,Denis Soulières,Aaron R. Hansen,Li X Wei,Tariq Aziz Khan,Karen Miller-Moslin,Mustimbo Roberts,Robert I. Haddad +22 more
TL;DR: In this article , the authors investigated whether first-line treatment with nivolumab plus ipilimumab vs nivolaumab alone improves the objective response rate in adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab
Peter Grell,Pavel Fabian,Marta Khoylou,Lenka Radová,Ondrej Slaby,Roman Hrstka,Rostislav Vyzula,Marian Hajduch,Marek Svoboda +8 more
TL;DR: This study is the first to prove the significance of Akt kinase isoform, activity and compartmentalization for the prediction of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer.
Tumor Expression of miR-10b, miR-21, miR-143 and miR-145 Is Related to Clinicopathological Features of Gastric Cancer in a Central European Population.
Radka Obermannova,Martina Redova-Lojova,Petra Vychytilova-Faltejskova,Peter Grell,William C. Cho,Milana Šachlová,Marek Svoboda,Rostislav Vyzula,Ondrej Slaby +8 more
TL;DR: The results indicate that selected tissue microRNAs have the potential to serve as relevant diagnostic and prognostic biomarkers of GC in a central European population.
21
Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
Alena Novakova-Jiresova,Katerina Kopeckova,Ludmila Boublikova,Renata Chloupková,Bohuslav Melichar,Lubos Petruzelka,Jindrich Finek,Ondrej Fiala,Peter Grell,Stanislav Batko,Zdenek Linke,Igor Kiss,Jana Prausová,Tomas Buchler +13 more
TL;DR: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials and is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.
Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
M. Elena Garralda,Aung Naing,Vladimir Galvao,Patricia LoRusso,Peter Grell,Philippe A. Cassier,Carlos Gomez-Roca,Iphigenie Korakis,David Bechard,L. Palova Jelinkova,Irena Adkins,Sascha Tillmanns,J Kiemle-Kallee,Aurélien Marabelle,Stéphane Champiat +14 more
TL;DR: SOT101 as monotherapy and in combination with pembrolizumab showed a favorable safety profile and highly promising efficacy signals with one ongoing CR and several long-lasting PRs were reported in CPI-naïve and CPI pretreated pts, including CPI-resistant tumors.
10